Skip to main content

Charles River Laboratories International, Inc.

corporate_fare Company Profile

Charles River Laboratories International, Inc.

CRL·NYSE·Industrial Applications And Services·CIK 0001100682

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services globally, operating in the United States, Europe, Canada, the Asia Pacific, and other international markets. The company is structured into three main segments. The Research Models and Services segment produces and sells rodents, including purpose-bred rats and mice, for research use. This segment also offers services supporting research models, such as genetically engineered models and services, insourcing solutions, and research animal diagnostic services, and is involved in the development and production of cell therapies. The Discovery and Safety Assessment segment provides in vitro and in vivo discovery services for novel drugs, molecule compounds, oligonucleotides, biotherapeutics, and antibodies, delivering preclinical candidates for safety assessment. It also offers safety assessment services, including toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics, alongside vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. It also offers specialized biologics testing outsourced by pharmaceutical and biotechnology companies, and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles for its contract development and manufacturing organization, and a strategic alliance with Francis Crick Institute (Crick), Inc. for Antibody-Drug Conjugate (ADC) drug discovery and development. Founded in 1947, Charles River Laboratories International, Inc. is headquartered in Wilmington, Massachusetts.

Charles River Laboratories International, Inc. (NYSE:CRL) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 22 items for CRL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 17 rated 8 or above. Recent SEC coverage for CRL spans 10-Q, 8-K, DEF 14A, 10-K.

Recent high-impact activity:

  • Charles River Bolsters CRO Services With Frontage Bioanalysis, DMPK Buy
  • Charles River 10-Q: Q3 Net Income Jumps to $333.1M on $201M Tax Benefit; Create the Future Targets $300M Savings
  • Charles River Beats Q3, Raises 2026 Guidance; Non-GAAP EPS Up 27.2%
  • Charles River Beats Q3, Lifts 2026 Guidance as Non-GAAP EPS Jumps 27%
  • Charles River Reaffirms 2026 Guidance at Upper End, Sets 2030 Targets

Financial Snapshot

Fiscal year ended December 27, 2025
Revenue
$4.02B
Net Income
-$144.34M
Diluted EPS
-$2.91
Op. Cash Flow
$737.65M
Free Cash Flow
$518.49M
Operating Income
$25.16M
Cash & Equivalents
$213.77M
Total Debt
$166K
Debt / Equity
0.00×
Net Margin
-3.6%
Shares Outstanding
49.22M sh
Source: 10-K · filed 2026-02-18 · accession 0001100682-26-000022

Short Interest & Short Volume

2.23 days to cover

FINRA reported short interest of 2,987,094 shares in CRL as of the October 30, 2026 settlement, a 5.4% increase from the prior period — about 2.2 days to cover at its recent average daily volume. On November 20, 2026, 49.2% of CRL volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)2,987,094 shares as of October 30, 2026
Change vs prior period▲ 5.4%
Days to cover2.23 at avg daily volume of 1,337,313
Daily short volume (FINRA facilities)49.2% of 414,137 shares on November 20, 2026
5-day average short volume52.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with C →
$315.43 +0.35% today
52-week range · as of 2026-11-04 $146.19 – $379.63
Market cap
$15.06B
Volume
1.2M (1.0× avg)
3-mo avg 1.1M
Live data · 2026-11-22 12:41 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CRL - Latest Insights

CRL
Nov 09, 2026, 6:10 AM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $337.44
Real-time Price: $315.43 info
Change: -$22.01 (-7%) info
Market Cap: $15.061B info
CRL
Nov 04, 2026, 9:03 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $342.99
Real-time Price: $315.43 info
Change: -$27.56 (-8%) info
Market Cap: $15.061B info
CRL
Nov 04, 2026, 7:04 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $362.01
Real-time Price: $315.43 info
Change: -$46.58 (-13%) info
Market Cap: $15.061B info
CRL
Nov 04, 2026, 7:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $362.00
Real-time Price: $315.43 info
Change: -$46.57 (-13%) info
Market Cap: $15.061B info
CRL
Sep 24, 2026, 8:12 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $278.01
Real-time Price: $315.43 info
Change: +$37.42 (+13%) info
Market Cap: $15.061B info
CRL
Sep 24, 2026, 8:00 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $277.33
Real-time Price: $315.43 info
Change: +$38.10 (+14%) info
Market Cap: $15.061B info
CRL
Aug 10, 2026, 7:37 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $267.49
Real-time Price: $315.43 info
Change: +$47.94 (+18%) info
Market Cap: $15.061B info
CRL
Aug 05, 2026, 2:03 PM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $259.99
Real-time Price: $315.43 info
Change: +$55.44 (+21%) info
Market Cap: $15.061B info
CRL
Aug 05, 2026, 9:21 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $257.00
Real-time Price: $315.43 info
Change: +$58.43 (+23%) info
Market Cap: $15.061B info
CRL
Aug 05, 2026, 7:33 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $253.00
Real-time Price: $315.43 info
Change: +$62.43 (+25%) info
Market Cap: $15.061B info
CRL
Aug 05, 2026, 7:15 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $253.00
Real-time Price: $315.43 info
Change: +$62.43 (+25%) info
Market Cap: $15.061B info
CRL
May 11, 2026, 5:01 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $168.46
Real-time Price: $315.43 info
Change: +$146.97 (+87%) info
Market Cap: $15.061B info
CRL
May 07, 2026, 4:14 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $181.68
Real-time Price: $315.43 info
Change: +$133.75 (+74%) info
Market Cap: $15.061B info
CRL
May 07, 2026, 7:14 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $181.75
Real-time Price: $315.43 info
Change: +$133.68 (+74%) info
Market Cap: $15.061B info
CRL
May 07, 2026, 7:04 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $179.07
Real-time Price: $315.43 info
Change: +$136.36 (+76%) info
Market Cap: $15.061B info
CRL
Mar 31, 2026, 7:50 AM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $159.72
Real-time Price: $315.43 info
Change: +$155.71 (+97%) info
Market Cap: $15.061B info
CRL
Feb 25, 2026, 7:34 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $166.06
Real-time Price: $315.43 info
Change: +$149.37 (+90%) info
Market Cap: $15.061B info
CRL
Feb 18, 2026, 4:39 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $158.00
Real-time Price: $315.43 info
Change: +$157.43 (+100%) info
Market Cap: $15.061B info
CRL
Feb 18, 2026, 9:21 AM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $154.89
Real-time Price: $315.43 info
Change: +$160.54 (+104%) info
Market Cap: $15.061B info
CRL
Feb 18, 2026, 7:13 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $160.00
Real-time Price: $315.43 info
Change: +$155.43 (+97%) info
Market Cap: $15.061B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets